PMID- 36795123
OWN - NLM
STAT- MEDLINE
DCOM- 20230615
LR  - 20240426
IS  - 1432-0851 (Electronic)
IS  - 0340-7004 (Print)
IS  - 0340-7004 (Linking)
VI  - 72
IP  - 7
DP  - 2023 Jul
TI  - Cisplatin resistance driver claspin is a target for immunotherapy in urothelial 
      carcinoma.
PG  - 2057-2065
LID - 10.1007/s00262-023-03388-5 [doi]
AB  - Bladder cancer is a major and fatal urological disease. Cisplatin is a key drug 
      for the treatment of bladder cancer, especially in muscle-invasive cases. In most 
      cases of bladder cancer, cisplatin is effective; however, resistance to cisplatin 
      has a significant negative impact on prognosis. Thus, a treatment strategy for 
      cisplatin-resistant bladder cancer is essential to improve the prognosis. In this 
      study, we established a cisplatin-resistant (CR) bladder cancer cell line using 
      an urothelial carcinoma cell lines (UM-UC-3 and J82). We screened for potential 
      targets in CR cells and found that claspin (CLSPN) was overexpressed. CLSPN mRNA 
      knockdown revealed that CLSPN had a role in cisplatin resistance in CR cells. In 
      our previous study, we identified human leukocyte antigen 
      (HLA)-A*02:01-restricted CLSPN peptide by HLA ligandome analysis. Thus, we 
      generated a CLSPN peptide-specific cytotoxic T lymphocyte clone that recognized 
      CR cells at a higher level than wild-type UM-UC-3 cells. These findings indicate 
      that CLSPN is a driver of cisplatin resistance and CLSPN peptide-specific 
      immunotherapy may be effective for cisplatin-resistant cases.
CI  - (c) 2023. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, 
      part of Springer Nature.
FAU - Yamada, Shuhei
AU  - Yamada S
AD  - Departments of Pathology, Sapporo Medical University School of Medicine, South-1 
      West-17, Chuo-Ku, Sapporo, Hokkaido, 060-8556, Japan.
AD  - Department of Renal and Genitourinary Surgery, Hokkaido University Graduate 
      School of Medicine, Sapporo, Hokkaido, 060-8648, Japan.
FAU - Miyata, Haruka
AU  - Miyata H
AD  - Department of Renal and Genitourinary Surgery, Hokkaido University Graduate 
      School of Medicine, Sapporo, Hokkaido, 060-8648, Japan.
FAU - Isono, Makoto
AU  - Isono M
AD  - Department of Urology, Abiko Toho Hospital, Abiko, 270-1166, Japan.
FAU - Hori, Kanta
AU  - Hori K
AD  - Departments of Pathology, Sapporo Medical University School of Medicine, South-1 
      West-17, Chuo-Ku, Sapporo, Hokkaido, 060-8556, Japan.
AD  - Department of Renal and Genitourinary Surgery, Hokkaido University Graduate 
      School of Medicine, Sapporo, Hokkaido, 060-8648, Japan.
FAU - Yanagawa, Junko
AU  - Yanagawa J
AD  - Departments of Pathology, Sapporo Medical University School of Medicine, South-1 
      West-17, Chuo-Ku, Sapporo, Hokkaido, 060-8556, Japan.
FAU - Murai, Aiko
AU  - Murai A
AD  - Departments of Pathology, Sapporo Medical University School of Medicine, South-1 
      West-17, Chuo-Ku, Sapporo, Hokkaido, 060-8556, Japan.
FAU - Minowa, Tomoyuki
AU  - Minowa T
AD  - Departments of Pathology, Sapporo Medical University School of Medicine, South-1 
      West-17, Chuo-Ku, Sapporo, Hokkaido, 060-8556, Japan.
AD  - Departments of Dermatology, Sapporo Medical University School of Medicine, 
      Sapporo, Hokkaido, 060-8556, Japan.
FAU - Mizue, Yuka
AU  - Mizue Y
AD  - Departments of Pathology, Sapporo Medical University School of Medicine, South-1 
      West-17, Chuo-Ku, Sapporo, Hokkaido, 060-8556, Japan.
FAU - Sasaki, Kenta
AU  - Sasaki K
AD  - Departments of Pathology, Sapporo Medical University School of Medicine, South-1 
      West-17, Chuo-Ku, Sapporo, Hokkaido, 060-8556, Japan.
AD  - Department of Dermatology, Asahikawa Medical University School of Medicine, 
      Asahikawa, Hokkaido, 078-8510, Japan.
FAU - Murata, Kenji
AU  - Murata K
AD  - Departments of Pathology, Sapporo Medical University School of Medicine, South-1 
      West-17, Chuo-Ku, Sapporo, Hokkaido, 060-8556, Japan.
FAU - Tokita, Serina
AU  - Tokita S
AD  - Departments of Pathology, Sapporo Medical University School of Medicine, South-1 
      West-17, Chuo-Ku, Sapporo, Hokkaido, 060-8556, Japan.
FAU - Nakatsugawa, Munehide
AU  - Nakatsugawa M
AD  - Department of Pathology, Tokyo Medical University Hachioji Medical Center, 
      Hachioji, Tokyo, 193-0998, Japan.
FAU - Iwabuchi, Sadahiro
AU  - Iwabuchi S
AD  - Department of Molecular Pathophysiology, Institute of Advanced Medicine, Wakayama 
      Medical University, Wakayama, Wakayama, 641-8509, Japan.
FAU - Hashimoto, Shinichi
AU  - Hashimoto S
AD  - Department of Molecular Pathophysiology, Institute of Advanced Medicine, Wakayama 
      Medical University, Wakayama, Wakayama, 641-8509, Japan.
FAU - Kubo, Terufumi
AU  - Kubo T
AD  - Departments of Pathology, Sapporo Medical University School of Medicine, South-1 
      West-17, Chuo-Ku, Sapporo, Hokkaido, 060-8556, Japan.
FAU - Kanaseki, Takayuki
AU  - Kanaseki T
AD  - Departments of Pathology, Sapporo Medical University School of Medicine, South-1 
      West-17, Chuo-Ku, Sapporo, Hokkaido, 060-8556, Japan.
FAU - Tsukahara, Tomohide
AU  - Tsukahara T
AD  - Departments of Pathology, Sapporo Medical University School of Medicine, South-1 
      West-17, Chuo-Ku, Sapporo, Hokkaido, 060-8556, Japan.
FAU - Abe, Takashige
AU  - Abe T
AD  - Department of Renal and Genitourinary Surgery, Hokkaido University Graduate 
      School of Medicine, Sapporo, Hokkaido, 060-8648, Japan.
FAU - Shinohara, Nobuo
AU  - Shinohara N
AD  - Department of Renal and Genitourinary Surgery, Hokkaido University Graduate 
      School of Medicine, Sapporo, Hokkaido, 060-8648, Japan.
FAU - Hirohashi, Yoshihiko
AU  - Hirohashi Y
AD  - Departments of Pathology, Sapporo Medical University School of Medicine, South-1 
      West-17, Chuo-Ku, Sapporo, Hokkaido, 060-8556, Japan. hirohash@sapmed.ac.jp.
FAU - Torigoe, Toshihiko
AU  - Torigoe T
AD  - Departments of Pathology, Sapporo Medical University School of Medicine, South-1 
      West-17, Chuo-Ku, Sapporo, Hokkaido, 060-8556, Japan. torigoe@sapmed.ac.jp.
LA  - eng
GR  - JPMJCR15G3/Japan Science and Technology Agency/
GR  - 20cm0106352h0002/Japan Agency for Medical Research and Development/
GR  - 22ama221317h0001/Japan Agency for Medical Research and Development/
GR  - 16770510/Japan Agency for Medical Research and Development/
GR  - 20H03460/Japan Society for the Promotion of Science/
GR  - 17H01540/Japan Society for the Promotion of Science/
PT  - Journal Article
DEP - 20230216
PL  - Germany
TA  - Cancer Immunol Immunother
JT  - Cancer immunology, immunotherapy : CII
JID - 8605732
RN  - Q20Q21Q62J (Cisplatin)
RN  - 0 (CLSPN protein, human)
RN  - 0 (Adaptor Proteins, Signal Transducing)
SB  - IM
MH  - Humans
MH  - Cell Line, Tumor
MH  - *Urinary Bladder Neoplasms/drug therapy/immunology/metabolism/therapy
MH  - Cisplatin/therapeutic use
MH  - *Drug Resistance, Neoplasm
MH  - Immunotherapy
MH  - *Adaptor Proteins, Signal Transducing/metabolism
MH  - Up-Regulation
MH  - T-Lymphocytes, Cytotoxic/cytology
MH  - Neoplastic Stem Cells/drug effects
PMC - PMC10992486
OTO - NOTNLM
OT  - Cisplatin resistance
OT  - Claspin
OT  - Immunotherapy
OT  - Urothelial carcinoma
COIS- The authors have no financial conflicts of interest to disclose.
EDAT- 2023/02/17 06:00
MHDA- 2023/06/15 06:42
PMCR- 2023/02/16
CRDT- 2023/02/16 11:04
PHST- 2022/11/10 00:00 [received]
PHST- 2023/01/25 00:00 [accepted]
PHST- 2023/06/15 06:42 [medline]
PHST- 2023/02/17 06:00 [pubmed]
PHST- 2023/02/16 11:04 [entrez]
PHST- 2023/02/16 00:00 [pmc-release]
AID - 10.1007/s00262-023-03388-5 [pii]
AID - 3388 [pii]
AID - 10.1007/s00262-023-03388-5 [doi]
PST - ppublish
SO  - Cancer Immunol Immunother. 2023 Jul;72(7):2057-2065. doi: 
      10.1007/s00262-023-03388-5. Epub 2023 Feb 16.